Tag: Blood Cancers
Search News
BCI at the 60th ASH Annual Meeting
14th January 2019
Researchers from our Centre for Haemato-Oncology attended the 60th American Society of Hematology (ASH) Annual Meeting and Exposition to showcase our blood cancer research.
Read more
CRUK Barts Centre welcomes two new Group Leaders
8th November 2018
We are pleased to welcome two new members of academic staff to the CRUK Barts Centre- Professor Victoria Sanz-Moreno and Professor Kamil R Kranc.
Read more
Accelerator Award to improve early detection and intervention of blood cancers
9th October 2018
BCI researchers are lead members of an international team to be funded by an Accelerator Award, which will bring together scientists from the UK, Spain and Italy in a bid to improve early detection and intervention of blood cancers.
Read more
Blood Cancer Awareness Month 2018
28th September 2018
Blood Cancer Awareness Month takes place every September to raise awareness of the challenges faced by those living with blood cancer. In the UK, blood cancer is the fifth most common cancer, with 240,000 people living with the disease and 38,000 people being diagnosed with a type of blood cancer each year.
Read more
CRUK Gibraltar Committee visit the BCI
18th July 2018
We were recently visited by two members of the CRUK Gibraltar Committee, Giovi and Deborah, who came to the BCI for a laboratory tour with Dr Ana Rio-Machin, a postdoctoral researcher in the Centre for Haemato-Oncology. Ana’s research focuses on leukaemia, a type of blood cancer in which patients present an abnormal growth of white blood cells.
Read more
Follicular lymphoma marked by spatial tumour heterogeneity
23rd March 2018
A research team at the BCI, Queen Mary University of London, led by Dr Jessica Okosun, Centre for Haemato-Oncology, has found that tumours at different sites within the same patient with follicular lymphoma can be genetically diverse. This suggests that a sole biopsy is incapable of capturing all the genetic events in any given individual and presents a significant challenge when providing targeted therapies to treat this disease.
Read more